Skip to content
PeptideAgent

Compounding pharmacies in New Jersey

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The New Jersey State Board of Pharmacy (Division of Consumer Affairs) regulates compounding pharmacies in New Jersey. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

New Jersey at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async not allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving New Jersey

No verified compounding pharmacies serving New Jersey are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in New Jersey

The Board of Pharmacy regulates pharmacy under the Pharmacy Practice Act of 2003 (N.J.S.A. 45:14-40 and following) and N.J.A.C. 13:39, including subchapter 11 on compounding sterile preparations. N.J.S.A. 45:14-73 requires any pharmacy located in another state that ships, mails, distributes, or delivers prescription legend drugs into New Jersey to register with the Board, submit its most recent home-state inspection report, and provide a toll-free line to a pharmacist with access to patient records; N.J.A.C. 13:39-4.20 implements the registration. Board rule N.J.A.C. 13:39-11.25 bars compounding a commercially available drug product unless the prescriber determines the change produces a significant difference for the patient. In its statement on semaglutide compounding (the version posted on the Board's site is dated November 6, 2023), the Board said that no salt form of semaglutide may be used in a compounded drug, and that a pharmacy using semaglutide base must ensure it is pharmaceutical grade, accompanied by a valid certificate of analysis, and sourced from an FDA-registered establishment. New Jersey has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [2] [3] [4] [5] [7]

Compounded GLP-1 access in New Jersey

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Board's 2023 statement independently bars semaglutide salt forms and requires documented, FDA-registered sourcing of semaglutide base. [5] [10]

Research use only sellers in New Jersey

New Jersey's food and drug law (N.J.S.A. Title 24) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act limits dispensing to licensed pharmacies. The Board's semaglutide statement also warns pharmacies against non-pharmaceutical-grade ingredients. [5] [6] [11]

New Jersey notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telemedicine under N.J.S.A. 45:1-61 and following. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, and the New Jersey Board of Pharmacy bars any salt form of semaglutide in compounding. [5] [10]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. New Jersey pharmacies apply the federal eligibility test and the Board's sourcing expectations for pharmaceutical-grade ingredients. [5] [8] [9]

How to check a compounding pharmacy in New Jersey

  1. Search the New Jersey State Board of Pharmacy (Division of Consumer Affairs) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration New Jersey requires before it ships to you. [1] [2] [3] [4] [5] [7]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in New Jersey. [5] [6] [11]

Common questions in New Jersey

What did the New Jersey Board of Pharmacy say about compounded semaglutide?

In a 2023 statement (the version on the Board's site is dated November 6, 2023) the Board said that no salt form of semaglutide may be used in compounding, and that semaglutide base must be pharmaceutical grade, carry a valid certificate of analysis, and come from an FDA-registered establishment. [5]

Is compounded semaglutide or tirzepatide still available in New Jersey?

Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and New Jersey also bars semaglutide salt forms, so routine compounded GLP-1 programs are not lawful. [5] [10]

Can a New Jersey pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [7] [8] [9]

All peptide legal questions for New Jersey

Sources

  1. [1]New Jersey State Board of Pharmacy (Division of Consumer Affairs)
  2. [2]New Jersey Pharmacy Practice Act, N.J.S.A. 45:14-40 and following, and N.J.A.C. 13:39 (Board laws and regulations)
  3. [3]N.J.S.A. 45:14-73, Registration of out-of-State pharmacies; requirements
  4. [4]N.J.A.C. 13:39-4.20, Out-of-State pharmacy registration
  5. [5]New Jersey State Board of Pharmacy: Statement concerning semaglutide compounding (posted version dated November 6, 2023)
  6. [6]N.J.S.A. Title 24, Food and drugs
  7. [7]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  9. [9]FDA: Pharmacy Compounding Advisory CommitteeFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts